Search clinical trials for: gemcitabine/carboplatin plus Iniparib

Total 589 results

Sanofi

Completed

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)

Squamous Cell Lung Cancer

Canada, Belgium, Spain, United States, France, Germany, Hungary, Israel, Italy, Luxembourg, Netherlands, Poland, Romania, United Kingdom
Sanofi
Breast Cancer Research Foundation

Completed

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Sanofi
BiPar Sciences

Completed

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Sanofi

Completed

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Advance Solid Tumors

Japan
Sanofi

Completed

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Breast Cancer

United States
Sanofi
Gynecologic Oncology Group

Completed

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Uterine Carcinosarcoma

United States
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
Shanghai Jiao Tong University School of Medicine
Shanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaborators

Recruiting

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

Recurrent Non-small Cell Lung Cancer

China
Cantargia AB
Spanish Breast Cancer Research Group

Recruiting

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple Negative Breast Cancer

Spain
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7 | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive... and other conditions

United States
Sanofi

Completed

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Neoplasm Malignant

United States
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
NCIC Clinical Trials Group

Completed

Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Head and Neck Cancer

Canada
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (GPMOC202)

Ovarian Cancer

Korea, Republic of
Associació per a la Recerca Oncologica, Spain
Pivotal S.L.; Merck, S.L., Spain

Completed

Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma (INDUCOMAIN)

Metastatic Urothelial Cancer

Spain
Sanofi

Completed

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer, Metastatic

Australia, Belgium, France, Italy, Netherlands, Spain
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
GlaxoSmithKline
Merck Sharp & Dohme LLC

Completed

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Neoplasms

United States, Australia, Spain, Italy, Japan, Netherlands, Canada, France, China
Hunan Province Tumor Hospital

Unknown

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Piramal Enterprises Limited

Terminated

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Malignant Pleural Effusion

United States
Yonsei University

Recruiting

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Breast Cancer

Korea, Republic of
Sanofi

Completed

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Solid Tumors
Assiut University

Recruiting

Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Urinary Bladder Cancer

Egypt
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Triple Negative Breast Cancer

United States, Australia
University of Alabama at Birmingham
Eli Lilly and Company

Completed

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Stage IV Non-Small Cell Lung Cancer

United States
University of Saskatchewan

Completed

Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC

Non Small Cell Lung Cancer

Canada
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Sanofi

Completed

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Solid Tumors

Belgium, Italy, United States, Spain
Tianjin Medical University Cancer Institute and...

Unknown

Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer

Metastatic Breast Cancer

China
Cancer Research UK

Terminated

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United Kingdom
SOTIO a.s.

Completed

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Ovarian Neoplasms | Ovarian Epithelial Cancer | Ovarian Cancer (OvCa)

Czechia, Poland, Germany
Sanofi

Completed

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

Spain
Tessa Therapeutics

Completed

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Nasopharyngeal Carcinoma

United States, Taiwan, Malaysia, Singapore, Thailand
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Pseudomyxoma Peritonei | Recurrent Endometrial Carcinoma | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Leydig Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Ovarian Stromal Cancer | Recurrent Ovarian Germ Cell Tumor | Recurrent Fallopian Tube Cancer | Recurrent... and other conditions

United States
Charite University, Berlin, Germany
Pfizer; Aventis Pharmaceuticals

Unknown

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

Small Cell Lung Cancer

Germany
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States
Fudan University

Recruiting

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer

China
Sanofi

Completed

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma

United States
National University Hospital, Singapore

Completed

Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer

Metastatic Breast Cancer

Singapore
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
Sichuan University
AstraZeneca

Terminated

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Non-small Cell Lung Cancer Metastatic | EGFR Activating Mutation

China
Ludwig-Maximilians - University of Munich
Eli Lilly and Company

Completed

Gemcitabine + Carboplatin in Breast Cancer

Breast Cancer
Sanofi

Completed

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Spain, France, Germany, Italy, United Kingdom

Search clinical trials for: gemcitabine/carboplatin plus Iniparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations